Although Fab mediated pathways e.g. induction of apoptosis by rituximab or downregulation/ blocking of receptor mediated pathways by transtuzumab/cetuximab along with Fc mediated pathways e.g. CDC or ADCC, are proposed mechanism based on the in-vitro experiments, the engagement of activating type 1 FcγR has been shown to be an absolute requirement for tumor targeting antibodies capable of depleting the target cells in-vivo including rituximab (anti-CD20), trastuzumab (anti-HER/neu), and cetuximab (EGFR) [5, 32, 35]. Here, ERBB2 is linked to neoplasm.